Hsbc Holdings PLC Has $727,000 Stake in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Hsbc Holdings PLC increased its stake in AMNEAL PHARMACEUTICALS by 44.4%, acquiring 26,651 shares to own a total of 86,712 shares worth approximately $727,000.
• Multiple other institutional investors, including GAMMA Investing LLC and Amalgamated Bank, also made significant changes to their positions, indicating a growing interest in AMNEAL PHARMACEUTICALS.
• Analysts have rated AMNEAL PHARMACEUTICALS with an average rating of "Buy" and a price target of $11.60, despite recent ratings adjustments by brokerages.

Hsbc Holdings PLC raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 44.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,712 shares of the company's stock after buying an additional 26,651 shares during the period. Hsbc Holdings PLC's holdings in Amneal Pharmaceuticals were worth $727,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of AMRX. Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 6.2% during the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after acquiring an additional 920,758 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Amneal Pharmaceuticals by 5.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock valued at $39,531,000 after acquiring an additional 278,653 shares during the period. Nuveen LLC acquired a new position in shares of Amneal Pharmaceuticals during the first quarter valued at approximately $19,581,000. Invesco Ltd. increased its stake in shares of Amneal Pharmaceuticals by 19.2% during the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company's stock valued at $19,045,000 after acquiring an additional 365,467 shares during the period. Finally, Northern Trust Corp boosted its holdings in Amneal Pharmaceuticals by 9.7% during the fourth quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock worth $14,076,000 after buying an additional 156,699 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total value of $2,619,308.72. Following the transaction, the executive vice president directly owned 152,426 shares in the company, valued at $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nikita Shah sold 6,340 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $9.50, for a total value of $60,230.00. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,390,828.50. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 in the last 90 days. Insiders own 26.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded up $0.00 on Friday, hitting $9.55. 225,326 shares of the company were exchanged, compared to its average volume of 1,666,451. The company's 50 day moving average price is $8.64 and its two-hundred day moving average price is $8.11. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $9.79. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 956.26 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.